ABEO
Abeona Therapeutics Inc.
$5.50
+$0.05(+1.01%)
60
Overall
80
Value
63
Tech
39
Quality
Market Cap
$217.93M
Volume
483.84K
52W Range
$4.00 - $7.54
Target Price
$19.71
Order:
Income Statement
| Metric | Trend | Chart | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $889.0K | $837.0K | $3.0M | -- | $10.0M | $3.0M | $1.4M | $3.5M | -- | $5.8M | ||
| Total Revenue | $889.0K | $837.0K | $3.0M | -- | $10.0M | $3.0M | $1.4M | $3.5M | -- | $5.8M | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | -- | -- | -- | -- | -- | -- | $450.0K | $1.6M | -- | $1.5M | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $889.0K | $837.0K | $3.0M | -- | $10.0M | $3.0M | $964.0K | $3.5M | -- | $4.3M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $24.8M | $-28.7M | $-61.2M | $77.1M | $91.4M | $92.8M | $46.2M | $50.6M | $64.2M | $93.7M | ||
| Research & Development | $10.7M | $17.0M | $38.7M | $48.6M | $30.1M | $38.7M | $29.0M | $31.1M | $34.4M | $26.8M | ||
| Research Expense | $10.7M | $17.0M | $38.7M | $48.6M | $30.1M | $38.7M | $29.0M | $31.1M | $34.4M | $26.8M | ||
| Selling, General & Administrative | $13.3M | $10.9M | $20.1M | $20.7M | $23.8M | $21.6M | $17.3M | $19.0M | $29.9M | $65.0M | ||
| General & Administrative Expenses | $13.3M | $10.9M | $20.1M | $20.7M | $23.8M | $21.6M | $17.3M | $19.0M | $29.9M | $65.0M | ||
| Salaries & Wages | $-4.8M | $-4.6M | $-8.2M | $-7.3M | $5.9M | $5.3M | -- | $4.8M | -- | -- | ||
| Depreciation & Amortization | $825.0K | $741.0K | $2.4M | $7.8M | $4.6M | $3.3M | $3.1M | $2.3M | $2.0M | -- | ||
| Depreciation & Amortization | $825.0K | $741.0K | $2.4M | $7.8M | $4.6M | $3.3M | $3.1M | $2.3M | -- | -- | ||
| Amortization | $-677.0K | $-534.0K | $-1.2M | $-5.2M | $32.5M | $117.0K | -- | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | $-1.6M | $32.9M | $2.4M | $-3.9M | $1.6M | -- | $1.9M | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-23.9M | $-27.8M | $-58.2M | $-77.1M | $-81.4M | $-89.8M | $-50.9M | $-47.1M | $-64.2M | $-89.4M | ||
| EBITDA | $-21.0M | $-26.6M | $-55.8M | $-69.3M | $-74.5M | $-76.8M | $-34.4M | $-62.0M | $-57.3M | $78.6M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | -- | -- | $11.0K | $400.0K | $4.1M | $3.7M | $736.0K | $418.0K | $4.2M | $3.7M | ||
| Interest Income Operating | -- | -- | -- | -- | -- | $40.0K | $431.0K | $2.1M | $4.2M | $5.6M | ||
| Intinc | $-6.0K | $-8.0K | -- | -- | $3.5M | -- | -- | -- | $4.2M | -- | ||
| Net Non-Operating Interest Income/Expense | $-6.0K | $-8.0K | $-11.0K | $-400.0K | $-4.1M | $-3.7M | $305.0K | $-418.0K | $-4.2M | $-3.7M | ||
| Gain on Sale of Securities | $2.0M | $525.0K | $1.5M | -- | -- | -- | -- | -- | -- | -- | ||
| Other Income/Expense | $-2.0M | $-525.0K | $-1.5M | -- | -- | $-9.0K | $5.9M | $8.8M | $-439.0K | $-6.5M | ||
| Other Special Charges | $2.0M | $525.0K | -- | -- | -- | -- | $11.5M | $-8.8M | $439.0K | $6.5M | ||
| SPECIAL ITEMS | ||||||||||||
| Special Income Charges | -- | -- | -- | -- | -- | $-32.5M | $-1.8M | -- | -- | -- | ||
| Impairment of Capital Assets | -- | -- | -- | -- | -- | $32.5M | $1.8M | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-21.9M | $-27.3M | $-58.2M | $-77.1M | $-80.1M | $-81.3M | $-39.0M | $-65.1M | $-60.2M | $75.0M | ||
| Pre-Tax Income | $-21.9M | $-27.3M | $-58.2M | $-77.5M | $-85.5M | $-93.5M | $-39.7M | $-55.3M | $-63.7M | $71.3M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $-14.0K | $-34.4M | -- | -- | -- | -- | $-8.3M | $-11.4M | $-679.0K | $100.0K | ||
| NET INCOME | ||||||||||||
| Net Income | $-21.9M | $-27.3M | $-56.7M | $-76.3M | $-84.2M | $-84.9M | $-39.7M | $-54.2M | $-63.7M | $71.2M | ||
| Net Income (Continuing Operations) | $-21.9M | $-27.3M | $-56.7M | $-76.3M | $-84.2M | $-84.9M | $-39.7M | $-54.2M | $-63.7M | $71.2M | ||
| Net Income (Discontinued Operations) | $-21.9M | $-27.3M | $-56.7M | $-76.3M | $-84.2M | $-84.9M | $-39.7M | $-54.2M | $-63.7M | $71.2M | ||
| Net Income (Common Stockholders) | $-21.9M | $-27.3M | $-56.7M | $-76.3M | $-84.2M | $-84.9M | $-43.5M | $-54.2M | $-63.7M | $71.2M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $70.6M | ||
| TOTALS | ||||||||||||
| Total Expenses | $24.8M | $-28.7M | $-61.2M | $77.1M | $91.4M | $92.8M | $46.7M | $50.6M | $64.2M | $95.3M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $1.4M | $1.7M | $1.9M | $2.0M | $3.7M | $3.9M | $7.9M | $21.4M | $41.0M | $53.0M | ||
| Average Shares Outstanding (Diluted) | $1.4M | $1.7M | $1.9M | $2.0M | $3.7M | $3.9M | $7.9M | $21.4M | $41.0M | $66.1M | ||
| Shares Outstanding | $1.6M | $1.9M | $1.9M | $3.3M | $4.0M | $5.9M | $17.7M | $27.4M | $48.5M | $57.0M | ||
| Basic EPS | -- | -- | -- | -- | $-22.75 | $-21.5 | $-5.53 | $-2.53 | $-1.55 | $1.34 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | $-22.75 | $-21.5 | $-5.53 | $-2.53 | $-1.55 | $1.34 | ||
| Diluted EPS | $-16 | $-16.5 | $-29.75 | $-37.75 | $-22.75 | $-21.5 | $-5.53 | $-2.53 | $-1.55 | $1.01 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | $-37.75 | -- | -- | -- | $-2.53 | $-1.55 | $1.01 | ||
| OTHER METRICS | ||||||||||||
| Accrued Preferred Stock Dividends | -- | -- | -- | -- | -- | -- | $3.8M | -- | -- | -- | ||
| Gain On Sale Of P P E | -- | -- | -- | -- | -- | -- | $292.0K | $-47.0K | -- | -- | ||
| Net Income From Other Gains Losses | -- | $-8.0K | $1.5M | $1.2M | $1.3M | $8.5M | -- | -- | -- | -- | ||
| Other Gand A | $13.3M | $10.9M | $20.1M | $20.7M | $23.8M | $21.6M | $17.3M | $19.0M | $29.9M | $65.0M | ||
| Other Impairment Of Capital Assets | -- | -- | -- | -- | -- | -- | $1.4M | $-1.1M | -- | -- | ||
| Preferred Stock Dividends | -- | -- | -- | -- | -- | -- | $3.8M | -- | -- | -- | ||
| Rent And Landing Fees | $13.3M | $10.9M | $20.1M | -- | -- | -- | -- | -- | -- | -- | ||
| Othspecchg | -- | -- | -- | -- | -- | $-15.0K | $-141.0K | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ABEO | $5.50 | +1.0% | 483.84K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Abeona Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW